Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter study of pomalidomide in myeloproliferative neoplasms with fibrosis
2009-010738-23Phase 2Completed
- Sponsor
- University Hospital Ulm
- Start
- Sep 2009
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in primary myelofibrosis (PMF), secondary myelofibrosis (SMF) and Myeloproliferative neoplasm unclassifiable (MPN-U), sponsored by University Hospital Ulm. Primary endpoint: Objective disease response. Started Sep 2009; status: completed.
02
Drugs
pomalidomide
03
Conditions
primary myelofibrosis (PMF)secondary myelofibrosis (SMF)Myeloproliferative neoplasm unclassifiable (MPN-U)
Beyond the preview
Go deeper on 2009-010738-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010738-23.